Kura Oncology and Kyowa Kirin submitted data from the KOMET-001 trial, which the agency will review and decide whether to approve the drug by Nov. 30.

TP53 mutations in AML confer resistance to CAR T-cell therapy through exhaustion of CAR T-cells, and dysregulation of the mevalonate and Wnt pathways in AML and CAR T-cells, respectively. Targeting ...